| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Zhu, Ling Wang, Jizheng Wang, Yilu Jia, Lei Sun, Kai Wang, Hu Zou, Yubao Tian, Tao Liu, Yan Zou, Juan Hui, Rutai Yuan, Zuyi Song, Lei |
| Spatial Coverage |
China |
| Description |
Author Affiliation: Zhu L ( Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shanxi, People's Republic of China.); Wang J ( State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.); Wang Y ( State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.); Jia L ( State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.); Sun K ( State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.); Wang H ( State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.); Zou Y ( State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.); Tian T ( State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.); Liu Y ( Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shanxi, People's Republic of China.); Zou J ( Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shanxi, People's Republic of China.); Hui R ( State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.); Yuan Z ( Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shanxi, People's Republic of China. Electronic address: zuyiyuan@mail.xjtu.edu.cn.); Song L ( State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. Electronic address: lsongqd@yahoo.com.) |
| Abstract |
BACKGROUND: Uric acid (UA) has been shown to be an independent risk factor for various cardiovascular diseases. However, its significance in hypertrophic cardiomyopathy (HCM) has not yet been evaluated. The objective of the present study was to evaluate clinical implications of plasma UA levels on the prognosis of patients with HCM. METHODS: A total of 588 adult patients with HCM were enrolled at FuWai Hospital from 1999-2011 and followed until 2014. The plasma levels of UA were measured at enrollment. RESULTS: During the follow-up of 5.2 ± 2.4 years, 44 (7.5%) patients had cardiovascular-related deaths, and 100 (17.0%) patients had cardiac events. Compared with the first tertile of UA concentration (< 284.6 µmol/L), patients in the highest tertile (> 358.7 µmol/L) had a higher risk for the development of adverse events: cardiovascular death (adjusted hazard ratio [HR], 3.10; 95% confidence interval [CI], 1.37-7.04; P = 0.007), all-cause mortality (adjusted HR, 2.33; 95% CI, 1.11-4.89; P = 0.025), cardiac events (adjusted HR, 4.20, 95% CI, 2.38-7.42; P < 0.001), heart failure events (adjusted HR, 3.46; 95% CI, 1.86-6.45; P < 0.001), and arrhythmic events (adjusted HR, 9.19; 95% CI, 2.40-35.25; P = 0.001). Similarly, the continuous variable of UA (for every 1 mg/dL higher concentration) was also an independent predictor for adverse outcomes: cardiovascular death (adjusted HR, 1.29; 95% CI, 1.11-1.49; P = 0.001), all-cause mortality (adjusted HR, 1.23; 95% CI, 1.07-1.41; P = 0.004), cardiac events (adjusted HR, 1.27; 95% CI, 1.15-1.41; P < 0.001), heart failure events (adjusted HR, 1.19; 95% CI, 1.06-1.33; P = 0.003), and arrhythmic events (adjusted HR, 1.60; 95% CI, 1.30-1.98; P < 0.001). CONCLUSIONS: Our results indicate that UA is an independent predictor of adverse outcomes in patients with HCM. |
| File Format |
HTM / HTML |
| ISSN |
0828282X |
| Issue Number |
10 |
| Volume Number |
31 |
| e-ISSN |
19167075 |
| Journal |
Canadian Journal of Cardiology |
| Language |
English |
| Publisher |
Elsevier |
| Publisher Date |
2015-10-01 |
| Publisher Place |
Great Britain (UK) |
| Access Restriction |
One Nation One Subscription (ONOS) |
| Subject Keyword |
Discipline Cardiology Cardiomyopathy, Hypertrophic Uric Acid Blood Adult Biological Markers Diagnosis Mortality Cause Of Death China Epidemiology Echocardiography Methods Female Humans Incidence Magnetic Resonance Imaging, Cine Male Middle Aged Outcome Assessment (health Care) Predictive Value Of Tests Prognosis Journal Article Research Support, Non-u.s. Gov't |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Cardiology and Cardiovascular Medicine |
